BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11061985)

  • 1. Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist.
    Cazzola M; Boveri B; Carlucci P; Santus P; DiMarco F; Centanni S; Allegra L
    Pulm Pharmacol Ther; 2000; 13(6):301-5. PubMed ID: 11061985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
    Cazzola M; Centanni S; Boveri B; Di Marco F; Santus P; Matera MG; Allegra L
    Respiration; 2001; 68(5):452-9. PubMed ID: 11694805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease.
    Nannini LJ; Flores DM
    Pulm Pharmacol Ther; 2003; 16(5):307-11. PubMed ID: 12877822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.
    Lazarus SC; Wong HH; Watts MJ; Boushey HA; Lavins BJ; Minkwitz MC
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1725-30. PubMed ID: 9412547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial.
    Silverman RA; Nowak RM; Korenblat PE; Skobeloff E; Chen Y; Bonuccelli CM; Miller CJ; Simonson SG
    Chest; 2004 Nov; 126(5):1480-9. PubMed ID: 15539716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.
    Lavorini F; Geri P; Luperini M; Maluccio NM; Mariani L; Marmai C; Pistolesi M; Fontana GA
    Br J Clin Pharmacol; 2004 Nov; 58(5):512-20. PubMed ID: 15521899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summary of clinical trials with zafirlukast.
    Calhoun WJ
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S238-45; discussion S245-8. PubMed ID: 9647606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C; Hattersley H; Di Scala L; Drollmann A
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
    Cazzola M; Santus P; D'Adda A; Pizzolato S; Di Marco F; Centanni S
    Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
    Virchow JC; Prasse A; Naya I; Summerton L; Harris A
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy.
    Smith LJ; Hanby LA; Lavins BJ; Simonson SG
    Ann Allergy Asthma Immunol; 1998 Jul; 81(1):43-9. PubMed ID: 9690572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?
    Grootendorst DC; Gauw SA; Baan R; Kelly J; Murdoch RD; Sterk PJ; Rabe KF
    Pulm Pharmacol Ther; 2003; 16(2):115-20. PubMed ID: 12670781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of nebulized levalbuterol in stable COPD.
    Datta D; Vitale A; Lahiri B; ZuWallack R
    Chest; 2003 Sep; 124(3):844-9. PubMed ID: 12970007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of zafirlukast in the treatment of patients with bronchial asthma.
    Tsai JJ; Chan SC; Ho CK; Su YC; Feng TC
    J Microbiol Immunol Infect; 2001 Mar; 34(1):63-70. PubMed ID: 11321130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients.
    Cakmak G; Demir T; Gemicioglu B; Aydemir A; Serdaroglu E; Donma O
    Tohoku J Exp Med; 2004 Dec; 204(4):249-56. PubMed ID: 15572850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.